ClinicalTrials.gg
RecruitingNCT06915246Updated Mar 27, 2026

A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

A Phase 2 interventional study of VI-0609 and BiCNU in Lymphoma, Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by VIVUS LLC. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by VIVUS LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,910 studies in Lymphoma with a site in United States — 162 open to participants now, 289 under way, 15 of them phase 3. Lymphoma · United States.

Planned enrollment
620th of 1,595
49 · median 36
Started
2025
with 34 others
Phase 2
668 of 1,910
36 open now
Primary completion
2027-03
later than 127 of 282 live
Registered
1,860th of 1,910
by date

Among the 1,910 studies in Lymphoma with a site in United States, this one is the 620th largest by planned enrollment of the 1,595 interventional ones that give a count, is one of 35 that started in 2025, is one of 668 in phase 2, reaches primary completion later than 127 of the 282 other live ones, and was the 1,860th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 435 are open to participants now.

Browse Lymphoma studies →

Open to participants now

162 of the 1,910 studies in Lymphoma with a site in United States are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 347 Lymphoma studies recruiting now, 228 (66%) set no upper age limit and 78 (22%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,910 studies in Lymphoma with a site in United States, or all of them as a file.
02

Study summary

A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.

03

Conditions studied

  • Lymphoma
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma

Keywords

  • Lymphoma
  • AHCT
  • BiCNU
  • Carmustine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults ≥ 18 years of age with a ≥ 6 months;
  • performance status ≥ 70%;
  • confirmed Hodgkin lymphoma or Non-Hodgkin lymphoma;
  • Candidate for AHCT consolidation therapy as assessed by their treating physician;
  • Achieved a complete or partial response;
  • Completed collection of at least 2.0 x 10\^6 CD34 cells/kg of autologous hematopoietic progenitor cells (HPCs) by apheresis;
  • Recovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to ≤ grade 2;
  • Clinical laboratory and organ function criteria meeting study ranges/limits ≥ 50%; > 65% of predicted measurement, DLCO ≥ 50% of predicted;
  • Seronegative for Ag/Ab combo, , active , and syphilis

Exclusion criteria

Exclusion Criteria:

  • Prior high-dose chemotherapy with stem cell transplant, or prior allogeneic transplantation;
  • Significant prior external beam dose-limiting radiation to a critical organ based on review of the prior radiation treatment records;
  • Use of any other medication or device, or concurrent biological, chemotherapy, or radiation therapy;
  • Myelodysplasia or any active other than HL or NHL, or \< 5 years remission from any other prior malignancy;
  • Any cytogenetic abnormality in the bone marrow that is known to be associated with or predictive of myelodysplasia;
  • Persistent marrow involvement (>10%) with HL or NHL after salvage cytoreductive therapy and before stem cell mobilization;
  • Not having sufficient bone marrow harvest to reach adequate cell dose for transplant;
  • Active or C viral infection or HBsAg positive;
  • Positive antibody;
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    VI-0609

    VI-0609 (Carmustine with Propylene Glycol)

    Drug: VI-0609

  • Active comparator
    BiCNU

    BiCNU (Carmustine with Ethanol)

    Drug: BiCNU

Interventions

  • DrugVI-0609

    Carmustine with Propylene Glycol

  • DrugBiCNU

    Carmustine with Ethanol

06

What researchers measure

Primary outcomes

  1. Evaluation of infusion-related toxicities

    Time frame: Within 24 hours post infusion

  2. Evaluation of unacceptable toxicities

    Time frame: From start of BEAM through Day 30 post-AHCT

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Lymphoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's planned 24 months is below that.

Counting every sponsor, half of 293 studies reached it within 61 months; a quarter within 36 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 8, 2025
StartActual
Mar 12, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Apr 30, 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06915246
Lead sponsor
VIVUS LLC
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Mar 12, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

VIVUS Clinical
Contact
clinical@vivus.com
+1-888-998-4887

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion